1. Development of Surface Chemical Strategies for Synthesizing Redox-Responsive Diatomite Nanoparticles as a Green Platform for On-Demand Intracellular Release of an Antisense Peptide Nucleic Acid Anticancer Agent.
- Author
-
Terracciano M, Fontana F, Falanga AP, D'Errico S, Torrieri G, Greco F, Tramontano C, Rea I, Piccialli G, De Stefano L, Oliviero G, Santos HA, and Borbone N
- Subjects
- B7-H1 Antigen, Cell Line, Tumor, Diatomaceous Earth, Disulfides, Ligands, Oxidation-Reduction, Peptides, Polyethylene Glycols chemistry, Programmed Cell Death 1 Receptor, Silicon Dioxide, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Nanoparticles chemistry, Peptide Nucleic Acids
- Abstract
Redox-responsive silica drug delivery systems are synthesized by aeco-friendly diatomite source to achieve on-demand release of peptide nucleic acid (PNA) in tumor reducing microenvironment, aiming to inhibit the immune checkpoint programmed cell death 1 receptor/programmed cell death receptor ligand 1 (PD-1/PD-L1) in cancer cells. The nanoparticles (NPs) are coated with polyethylene glycol chains as gatekeepers to improve their physicochemical properties and control drug release through the cleavable disulfide bonds (S-S) in a reductive environment. This study describes different chemical conditions to achieve the highest NPs' surface functionalization yield, exploring both multistep and one-pot chemical functionalization strategies. The best formulation is used for covalent PNA conjugation via the S-S bond reaching a loading degree of 306 ± 25 µg
PNA mg-1 DNPs . These systems are used for in vitro studies to evaluate the kinetic release, biocompatibility, cellular uptake, and activity on different cancer cells expressing high levels of PD-L1. The obtained results prove the safety of the NPs up to 200 µg mL-1 and their advantage for controlling and enhancing the PNA intracellular release as well as antitumor activity. Moreover, the downregulation of PD-L1 observed only with MDA-MB-231 cancer cells paves the way for targeted immunotherapy., (© 2022 The Authors. Small published by Wiley-VCH GmbH.)- Published
- 2022
- Full Text
- View/download PDF